Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience

American Journal of Hematology

Volumn 87, Issue 6, 2012, Pages 631-634

  Barba, Pere ^a   Sampol, Antonia ^b   Calbacho, María ^c   Gonzalez, José ^d   Serrano, Josefina ^e   Martínez Sánchez, Pilar ^f   Fernández, Pascual ^g   García Boyero, Raimundo ^h   Bueno, Javier ^a   Ribera, Josep Maria ⁱ  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DASATINIB; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; THIOTEPA; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LETTER; LIVER TOXICITY; LYMPHOBLASTOMA; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; SEPTIC SHOCK; SIDE EFFECT; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG EVALUATION; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SPAIN; YOUNG ADULT;

EID: 84861339231     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23167     Document Type: Letter

References (21)

1. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
2. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol 2008; 26: 1843-1849.
3. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944-950.
4. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia (ALL) in adult patients included in four consecutive risk-adapted trials from the PETHEMA Study Group. Haematologica 2010; 95: 589-596.
5. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113: 3186-3191.
6. Martino R, Bellido M, Brunet S, et al. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: Results of a prospective trial. Haematologica 1999; 84: 505-510.
7. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995; 55: 2847-2852.
8. Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005; 55: 361-368.
9. Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23: 2259-2264.
10. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009; 147: 371-378.
11. Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer 2010; 54: 687-693.
12. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917-1923.
13. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 20111; 118: 6043-6049.
14. O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011; 154: 482-485.
15. Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: A phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 2010; 151: 430-434.
16. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762-1769.
17. Grigoleit GU, Kapp M, Tan SM, et al. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: Results from a case series. Leuk Lymphoma 2009; 50: 2071-2074.
18. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia 1993; 7: 378-383.
19. Cheson BD, Vena DA, Foss FM, et al. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994; 12: 2216-2228.
20. National Cancer Institute. Common Toxicity Criteria for Adverse Events. Version 3.0. Bethesda, MD: National Cancer Institute; 2003.
21. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.